CD8A and fatty liver disease: No significant improvement in hepatic steatosis, fibrosis, or biochemical markers (ALT, AST, cholesterol, etc.). Stabilization of CD8+ T lymphocytes and  ZO-1 expression in probiotics group (vs. reduction in placebo).